Wired

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

By Wired

1 min read
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Technology & Digital Transformation

Related Insights